China aims to overtake the United States in biopharma by running the same playbook it has employed in other sectors: a coordinated, state-led strategy that combines subsidies with scale and speed.
The best way to fend off Beijing’s ambitions isn’t to copy its tactics or launch another trade war. It’s to stop punishing U.S. pharmaceutical companies and let them outcompete their rivals.